Gotenburg study : PSA screening halves mortality from prostate cancer
from Medscape Medical News
New data from a Swedish study show that population screening with prostate-specific antigen (PSA) in men between 50 and 69 years of age reduced prostate cancer mortality by almost half during a follow-up period of 14 years. The finding was published online in Lancet Oncology. "In this trial, prostate cancer screening was well accepted by the general population and can result in a relevant reduction in cancer mortality, greater than that reported in screening for breast and colorectal cancer," conclude the researchers, headed by Jonas Hugosson, MD, from the Department of Urology at the University of Gotenburg, Sweden.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063